Ravi Shekhar

Ravi Shekhar

Auto-generated profile, based on publicly available information

Ravi Shekhar

Department of Pharmaceutics, Institute of Pharmacy and Paramedical Sciences, Dr. Bhimrao Ambedkar University, Chhalesar Campus, Agra, Uttar Pradesh, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2024 in Letters in Organic Chemistry
Verified
Journal Article
Closed access
PDF file
Kuldeep SinghKuldeep Singh
Kuldeep Singh
BBBharat Bhushan
Bharat Bhushan
AVAjit Kumar Varma
Ajit Kumar Varma
RSRavi Shekhar
Ravi Shekhar
RSRajeev Kumar Sharma
Rajeev Kumar Sharma
Mohit AgrawalMohit Agrawal
Mohit Agrawal
The benzimidazole scaffold is a promising nucleus for developing novel therapeutic agents for ulcer treatment. Its unique chemical structure provides desirable pharmacological properties, such as excellent bioavailability, metabolic stability, and low toxicity, making it an attractive candidate for ulcer treatment. Several benzimidazole derivatives have shown significant anti-ulcer activity in preclinical and clinical studies, acting through multiple pathways, including inhibition of gastric acid secretion, suppression of gastric inflammation, and promotion of mucosal protection. Some benzimidazole derivatives have also demonstrated anti-Helicobacter pylori activity, suggesting their potential for eradicating bacteria associated with ulcer formation. However, challenges such as poor solubility and limited selectivity remain. Various approaches, such as prodrug design and formulation optimization, have been explored to overcome these issues and improve the therapeutic profile of benzimidazole derivatives. Overall, the benzimidazole scaffold holds great promise as a nucleus for developing novel anti-ulcer agents. Further research and optimization efforts are needed to harness its full potential and translate it into effective treatments for ulcers. With continued advancements in medicinal chemistry and drug design, benzimidazole-based compounds may offer new therapeutic options for patients suffering from ulcers and related gastrointestinal disorders. Hence, this review highlights the knowledge about benzimidazole scaffold, the mechanism of ulcer formation, and various benzimidazole derivatives with anti-ulcer activity, which can be further studied in pre-clinical and clinical trials.

28 June 2022 in EXCLI Journal
Verified
Journal Article
Open access
ASAkshansh Sharma
Akshansh Sharma
RTRajiv Tonk
Rajiv Tonk
RSRavi Shekhar
Ravi Shekhar
SDSushil Dohare
Sushil Dohare
Deepak KumarDeepak Kumar
Deepak Kumar